Replies to post #757626 on NorthWest Biotherapeutics Inc (NWBO)

[Smitty5150]

Once again, a bunch of lip-service with zero details. A big let down.

[RobotDroid]

Too sad how you point out the BS fluff and ignore the fact ths company is a failure due to a failure of leadership.

[GoodGuyBill]

Does NWBO has a license agreement with Oncovir, Inc for the use of Hiltonol® (i.e. Poly-ICLC)?

Hiltonol® IS a TLR antagonist, right?

[KRISGO]

We should find a way to reach out to management and get clarity on the following:

The Company has undertaken discussions and negotiations with a number of companies who have products that could serve as booster agents either in the manufacturing of DCVax products or in combination treatment regimens with DCVax or both. The Company has completed a License and Supply Agreement with a company for one such agent, which is a TLR (toll like receptor) agonist, and the Company is now in the process of collaborating with that Company to design a clinical trial of a combination treatment regimen. The Company has already identified lead investigators for this trial, and anticipates submitting the IND for this trial to the FDA in Q2 2025. The Company plans to announce the trial when the IND has been cleared by the FDA. The Company is also testing this TLR agonist in its internal lab research on enhanced versions of DCs, as described below.

- This is old news, and it's likely to appear again in the Q next month when they release it on May 15th, since the second quarter ends in June, giving them the option to delay. The real question is whether they will proceed with this regardless of the outcome of the MAA approval decision.

The Company has been in discussions since mid-2024 with a different company to in-license a different type of booster agent – one that big pharma has been trying for years to develop as a treatment itself. The Company executed a Material Transfer Agreement with that company and has been testing samples of this agent in internal lab research as described below.

- Old news and it's likely to appear again in the next Q

The Company has also been in negotiations since early Q4 2024 for potential acquisition of another company with a dendritic cell related technology. The Company hopes to complete these negotiations during Q2 or Q3 2025.

- Unless we receive MHRA approval and support from a big pharma, it’s risky to move forward with these kinds of deals due to our current stock trading situation. As Femike mentioned, they could do a reverse split and secure enough funding to move forward, but this will likely reduce our shareholders' value, possibly by as much as 10% of what we’re worth now.